October 2018 Briefing – Nephrology

Here are what the editors at HealthDay consider to be the most important developments in Nephrology for October 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Link Between Statins, Non-CVD Outcomes Lacks Evidence

WEDNESDAY, Oct. 31, 2018 (HealthDay News) — There is a lack of convincing evidence for an association between statin use and non-cardiovascular disease (CVD) outcomes, according to a review published in the Oct. 16 issue of the Annals of Internal Medicine.

Abstract/Full Text (subscription or payment may be required)

AMA Announces Initiative to Reinvent Physician Training

TUESDAY, Oct. 30, 2018 (HealthDay News) — The American Medical Association (AMA) today announced a new $15 million competitive grant initiative, the “Reimagining Residency” initiative, aimed at improving residency training.

More Information

Many Hospitals Noncompliant With Record Request Regulations

MONDAY, Oct. 29, 2018 (HealthDay News) — Among top-ranked U.S. hospitals, data reveal discrepancies in information provided to patients regarding medical records release processes as well as noncompliance with state and federal regulations, according to a study published online Oct. 5 in JAMA Network Open.

Abstract/Full Text

ASN: Home Dialysis Associated With Improved Survival

MONDAY, Oct. 29, 2018 (HealthDay News) — Home hemodialysis (HHD) is associated with better survival than in-center hemodialysis (IHD) among incident dialysis patients, according to a study presented at the American Society of Nephrology’s Kidney Week, held Oct. 23 to 28 in San Diego.

Abstract
More Information

In Complicated UTI, Cefiderocol Noninferior to Imipenem-Cilastin

MONDAY, Oct. 29, 2018 (HealthDay News) — For complicated urinary tract infections caused by multidrug-resistant Gram-negative uropathogens, the siderophore cephalosporin cefiderocol is non-inferior to imipenem-cilastatin, according to a study published online Oct. 25 in The Lancet Infectious Diseases.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Trump Administration Announces Plan to Cut Drug Prices

FRIDAY, Oct. 26, 2018 (HealthDay News) — In an effort to cut high drug costs, the prices paid by Medicare for certain prescription drugs would be based on those in other advanced industrial nations, according to a proposal announced Oct. 25 by the Trump administration.

HHS Study
New York Times Article

Pace of Change Has Accelerated in Alternative Payment Models

THURSDAY, Oct. 25, 2018 (HealthDay News) — The impact of alternative payment models (APMs) on physician practices has been described in a study published by the RAND Corp. and the American Medical Association.

More Information

Allopurinol Linked to Reduced Risk for CKD Stage ≥3 in Gout